How I Treat High-Risk Patients with Essential Thrombocythemia or Polycythemia Vera
Jason Gotlib, MD, MS, Stanford University
Friday, September 8, 2017 8:30 a.m.
Fairmont Chicago, Millennium Park, Chicago, IL
Risk stratification in essential thrombocythemia (ET) and polycythemia vera (PV) is critical for estimating the likelihood of vascular events and disease transformation, and for guiding treatment options. This session will review prognostic risk models for ET and PV, as well the historical and contemporaneous data that have informed the selection of cytoreductive therapies for these myeloproliferative neoplasms. Dr. Gotlib will discuss the role of hydroxyurea, [PEG]-interferon-α, and Ruxolitinib, and will highlight the new NCCN management algorithms for PV and ET.
About the Speaker
Jason Gotlib, MD, is Professor of Medicine and Director of the Fellowship Training Program in the Division of Hematology at the Stanford University School of Medicine/Stanford Cancer Institute. His clinical and translational research program is focused on trial evaluation of novel biologics for myeloproliferative neoplasms (MPNs) and identification of inherited susceptibility alleles for these diseases. Dr. Gotlib has been a key investigator in the clinical development of JAK inhibitors for myelofibrosis and tyrosine kinase inhibitors for eosinophilic neoplasms and advanced systemic mastocytosis.
back to top